AVEO Pharmaceuticals Profit Margin 2009-2021 | AVEO
Current and historical gross margin, operating margin and net profit margin for AVEO Pharmaceuticals (AVEO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. AVEO Pharmaceuticals net profit margin as of June 30, 2021 is -398.34%.
|AVEO Pharmaceuticals Annual Profit Margins
|AVEO Pharmaceuticals Quarterly Profit Margins
||Medical - Biomedical and Genetics
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.